Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab watch-and-wait in localized dMMR/MSI-H gastric or OGJ adenocarcinoma
2023-506102-39-00Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of dostarlimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 cohorts), sponsored by GERCOR. Primary endpoint: Clinical complete response rate at 1 year. Planned start Oct 2023; status: authorised.
02
Drugs
dostarlimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2023-506102-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506102-39-00.